Atara Biotherapeutics (LTS:0HIY) ROCE % : -356.53% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Atara Biotherapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Atara Biotherapeutics's annualized ROCE % for the quarter that ended in Dec. 2023 was -356.53%.

Atara Biotherapeutics ROCE % Historical Data

The historical data trend for Atara Biotherapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atara Biotherapeutics ROCE % Chart

Atara Biotherapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-89.86

-76.18

-78.49

-69.08

-168.85

Atara Biotherapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-100.35	-110.46	-137.37	-194.39	-356.53

Atara Biotherapeutics ROCE % Calculation

Atara Biotherapeutics's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-270.826	/	( ( (376.42 - 78.916)	+	(165.504 - 142.226) )	/ 2 )
	=	-270.826	/	( (297.504	+	23.278)	/ 2 )
	=	-270.826	/	160.391
	=	-168.85 %

Atara Biotherapeutics's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-237.052	/	( ( (188.788 - 79.089)	+	(165.504 - 142.226) )	/ 2 )
	=	-237.052	/	( ( 109.699	+	23.278 )	/ 2 )
	=	-237.052	/	66.4885
	=	-356.53 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Atara Biotherapeutics (LTS:0HIY) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Atara Biotherapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Atara Biotherapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Atara Biotherapeutics (LTS:0HIY) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atara Biotherapeutics Inc (LTS:0HIY) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

ATRA:USA AT2:Germany AT2:Germany

Address

2380 Conejo Spectrum St, Suite 200, Thousand Oaks, CA, USA, 91320

Website

https://www.atarabio.com

Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).

Atara Biotherapeutics (LTS:0HIY) Headlines

No Headlines